Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | GRB2 | P62993 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028199 | 0.92 | CMA1 (0.40) | KMT2AOPRM1OPRD1OPRK1REN | |
| SCHEMBL30028577 | 0.84 | KMT2A (0.45) | KMT2AF2SMN1; SMN2CMA1 | |
| SCHEMBL30543475 | 0.82 | GRB2 (0.41) | KMT2AOPRM1OPRD1CAPN1GRB2 | |
| SCHEMBL35211230 | 0.80 | F2 (0.40) | OPRM1OPRD1OPRK1F2CMA1 | |
| SCHEMBL31347336 | 0.78 | CAPN1 (0.42) | OPRM1OPRD1NAA50CAPN1APLNR | |
| SCHEMBL30138992 | 0.77 | CAPN1 (0.40) | OPRM1OPRD1F2CAPN1 | |
| SCHEMBL30493192 | 0.77 | ITGB1 (0.36) | F2CMA1 | |
| SCHEMBL31501249 | 0.75 | APLNR (0.41) | OPRM1OPRD1OPRK1CAPN1GRB2 | |
| SCHEMBL31347345 | 0.75 | CMA1 (0.37) | KMT2AOPRM1OPRD1NAA50APLNR | |
| SCHEMBL4258292 | 0.75 | F2 (0.39) | NAA50F2APLNRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4598938-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | Eli Lilly and Company (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024077149-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | ELI LILLY AND COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | IAPP, GLP1R, VIP | KMT2A 3022/4885OPRM1 3191/4885OPRD1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.